Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade

International Journal of Cancer

Volumn 125, Issue 3, 2009, Pages 596-602

  Dünnebier, Thomas ^a   Bermejo, Justo Lorenzo ^b   Haas, Susanne ^c   Fischer, Hans Peter ^c   Pierl, Christiane B ^d   Justenhoven, Christina ^e,g   Brauch, Hiltrud ^e,g   Baisch, Christian ^f   Gilbert, Michael ^a   Harth, Volker ^d,f   Spickenheuer, Anne ^d   Rabstein, Sylvia ^d   Pesch, Beate ^d   Brüning, Thomas ^d   Ko, Yon Dschun ^f   Hamann, Ute ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^f Johanniter Krankenhaus   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Breast cancer progression; Multiple imputation; SUMOylation; Tumor grade; UBC9 polymorphisms

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN UBC9; SUMO PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; BREAST CANCER; CANCER SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE FREQUENCY; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HOMOZYGOTE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN; SUMO-1 PROTEIN; UBIQUITIN-CONJUGATING ENZYMES;

EID: 67650046370     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24286     Document Type: Article

References (37)

1. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004;73:355-82.
2. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 2007;8:947-56.
3. Muller S, Hoege C, Pyrowolakis G, Jentsch S. SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2001;2:202-10.
4. Xirodimas DP, Chisholm J, Desterro JM, Lane DP, Hay RT. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 2002;528:207-11.
5. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitinrelated modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998;17:61-70.
6. Bies J, Markus J, Wolff L. Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity. J Biol Chem 2002;277:8999-9009.
7. Muller S, Berger M, Lehembre F, Seeler JS, Haupt Y, Dejean A. c-Jun and p53 Activity is modulated by SUMO-1 modification. J Biol Chem 2000;275:13321-9.
8. Gostissa M, Hengstermann A, Fogal V, Sandy P, Schwarz SE, Scheffner M, Del Sal G. Activation of p53 by conjugation to the ubiquitinlike protein SUMO-1. EMBO J 1999;18:6462-71.
9. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. EMBO J 1999;18:6455-61.
10. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 2005;19:2671-84.
11. Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A, Milgrom E. Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 2003;278:12335-43.
12. Kotaja N, Karvonen U, Janne OA, Palvimo JJ. The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 2002;277:30283-8.
13. Wu H, Sun L, Zhang Y, Chen Y, Shi B, Li R, Wang Y, Liang J, Fan D, Wu G, Wang D, Li S, et al. Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J Biol Chem 2006;281:21848-56.
14. McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res 2002;8:1127-38.
15. Moschos SJ, Smith AP, Mandic M, Athanassiou C, Watson-Hurst K, Jukic DM, Edington HD, Kirkwood JM, Becker D. SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene 2007;26:4216-25.
16. Mo YY, Yu Y, Theodosiou E, Rachel Ee PL, Beck WT. A role for Ubc9 in tumorigenesis. Oncogene 2005;24:2677-83.
17. Cheng J, Bawa T, Lee P, Gong L, Yeh ET. Role of desumoylation in the development of prostate cancer. Neoplasia 2006;8:667-76.
18. Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep 2004;11:1319-24.
19. Pesch B, Ko Y, Brauch H, Hamann U, Harth V, Rabstein S, Pierl C, Fischer HP, Baisch C, Justenhoven C, Ranft U, Bruning T. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 2005;20:699-711.
20. Justenhoven C, Hamann U, Pesch B, Harth V, Rabstein S, Baisch C, Vollmert C, Illig T, Ko YD, Bruning T, Brauch H. ERCC2 genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol Biomarkers Prev 2004;13:2059-64.
21. Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Bruning T, Vollmert C, Illig T, Dippon J, et al. The CYP1B1-1358-GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 2008;111:171-7.
22. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
23. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
24. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007;39:906-13.
25. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. Increased incidence of small and well-differentiated breast tumours in postmenopausal women following hormone-replacement therapy. Int J Cancer 2001;92:919-22.
26. Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Moller S, Rank F, Ottesen B, Lynge E. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 2004;91:644-50.
27. Borgquist S, Anagnostaki L, Jirstrom K, Landberg G, Manjer J. Breast tumors following combined hormone replacement therapy express favorable prognostic factors. Int J Cancer 2007;120:2202-7.
28. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188:143-60.
29. Daniels RJ, Peden JF, Lloyd C, Horsley SW, Clark K, Tufarelli C, Kearney L, Buckle VJ, Doggett NA, Flint J, Higgs DR. Sequence, structure and pathology of the fully annotated terminal 2 Mb of the short arm of human chromosome 16. Hum Mol Genet 2001;10:339-52.
30. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
31. Zhao J. Sumoylation regulates diverse biological processes. Cell Mol Life Sci 2007;64:3017-33.
32. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001;92:37-45.
33. Ferrero JM, Ramaioli A, Formento JL, Francoual M, Etienne MC, Peyrottes I, Ettore F, Leblanc-Talent P, Namer M, Milano G. P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol 2000;11:393-7.
34. Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, Han QX, Shen ZZ, Fontana JA. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997;74:529-34.
35. Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. MDM2 protein expression is a negative prognostic marker in breast carcinoma. Mod Pathol 2006;19:69-74.
36. Raaphorst FM, Meijer CJ, Fieret E, Blokzijl T, Mommers E, Buerger H, Packeisen J, Sewalt RA, Otte AP, van Diest PJ. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003;5:481-8.
37. Riising EM, Boggio R, Chiocca S, Helin K, Pasini D The polycomb repressive complex 2 is a potential target of SUMO modifications. PLoS ONE 20083:e2704.